A randomized, double-blind, placebo-controlled, and food effects, bridging clinical study of KPG-818 in healthy subjects in China
Latest Information Update: 23 Sep 2024
Price :
$35 *
At a glance
- Drugs KPG 818 (Primary)
- Indications Behcet's syndrome; Crohn's disease; Haematological malignancies; Inflammatory bowel diseases; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kangpu Biopharmaceuticals
- 23 Sep 2024 New trial record
- 20 Sep 2024 According to a Kangpu Biopharmaceuticals media release, company announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects in China.